Companies › Prime Medicine
1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Nov 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PM577a Prime editing therapy to correct p.H1069Q mutation in ATP7B gene | ATP7B | Phase 1 | Wilson Disease | Nov 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07748403 | PM577a | Phase 1 | Wilson Disease | Metabolic and endocrine | Nov 2028 |
Cash and short-term investments of $95m on 2026-06-30; operating cash outflow about $170m a year; runway about 7 months at that burn, to Jan 2027
Press releases filed as 8-K in the last year:
Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.